

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/803,575</td> </tr> <tr> <td>Filing Date</td> <td>March 17, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Jerome C. Bressi</td> </tr> <tr> <td>Group Art Unit</td> <td>1625</td> </tr> <tr> <td>Examiner Name</td> <td>Celia C. Chang</td> </tr> <tr> <td>Attorney Docket Number</td> <td>HDAC-5005-C1</td> </tr> </table>		Application Number	10/803,575	Filing Date	March 17, 2004	First Named Inventor	Jerome C. Bressi	Group Art Unit	1625	Examiner Name	Celia C. Chang	Attorney Docket Number	HDAC-5005-C1
Application Number	10/803,575														
Filing Date	March 17, 2004														
First Named Inventor	Jerome C. Bressi														
Group Art Unit	1625														
Examiner Name	Celia C. Chang														
Attorney Docket Number	HDAC-5005-C1														
Sheet	9	of	15												

CC	KS	WO 00/021979 A2 & A3	4/20/2000	FUJISAWA PHARMACEUTICAL CO., LTD.		
	KT	WO 00/023567 A2 & A3	4/27/2000	NOVARTIS AG		
	KU	WO 00/52033 A1	9/8/2000	JAPAN ENERGY CORPORATION		
	KV	WO 00/56917 A1	9/28/2000	CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.		
	KW	WO 00/418045 A1 3-15-2004	10/8/2000	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	KX	WO 00/81576 A1	10/19/2000	SMITHKLINE BEECHAM CORPORATION		
	KY	WO 00/71703 A2 & A3	11/30/2000	METHYLGENE INC.		
	KZ	WO 01/07042 A1	2/1/2001	MERCK & CO., INC.		
	LA	WO 01/14581 A3	3/1/2001	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
	LB	WO 01/16106 A1	3/8/2001	SCHERING AKTIENGESELLSCHAFT		
	LC	WO 01/17514 A1	3/15/2001	SALK INSTITUTE OF BIOLOGICAL STUDIES		
	LD	WO 01/018045 A1	3/15/2001	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK		
	LE	WO 01/18171 A2 & A3	3/15/2001	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	LF	WO 01/27314 A1	4/18/2001	MERCK & CO., INC.		
	LG	WO 01/38322 A1	5/31/2001	METHYLGENE, INC.		
	LH	WO 01/42437 A2 & A3	6/14/2001	AXYS PHARMACEUTICALS, INC.		
	LI	WO 01/67107 A1	9/13/2001	IMPERIAL COLLEGE INNOVATIONS LIMITED		
	LJ	WO 01/70875 A3	9/27/2001	METHYLGENE, INC.		
	LK	WO 01/72784 A2 & A3	10/4/2001	FILGEN BIOSCIENCES, INC.		
	LL	WO 01/72737 A1	10/4/2001	SMITHKLINE BEECHAM CORPORATION		
	LM	WO 02/06307 A1	1/24/2002	FUJISAWA PHARMACEUTICAL CO., LTD.		
	LN	WO 02/08273 A2 & A3	1/31/2002	MILLENNIUM PHARMACEUTICALS, INC.		
	LO	WO 02/07722 A2 & A3	1/31/2002	GEORG-SPEYER-HAUS		
	LP	WO 02/15921 A2 & A3	2/28/2002	GOVERNEMENT OF UNITED STATES OF AMERICA, represented by SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	LQ	WO 02/22133 A1	3/21/2002	VIRGINIA COMMONWEALTH UNIVERSITY		
	LR	WO 02/22577 A3	3/21/2002	NOVARTIS AG		
CC	LS	WO 02/26696 A1	4/4/2002	PROLIFIX LIMITED		


Examiner Signature	/Celia Chang/	Date Considered	08/22/2006
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/803,575		
		Filing Date	March 17, 2004		
		First Named Inventor	Jerome C. Bressi		
		Group Art Unit	1625		
		Examiner Name	Celia C. Chang		
Sheet	1	of	2	Attorney Docket Number	HDAC-5005-C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
CC	AA	US 5,977,108	11/2/1999	Kouichi Kikuchi et al.	
CC	AB	US 6,099,851	8/8/2000	Kenneth M. Weisman et al.	
CC	AC	US 6,541,661	4/1/2003	Daniel Delorme et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² - Number ² - Kind Code ² (if known)				
CC	AD	EP 0 354 549 A2	2/14/1990	Konica Corporation		
	AE	EP 0 378 991 A1	7/25/1990	Ciba-Geigy AG		
	AF	EP 0 847 992 A1	6/14/1998	Mitsui Chemicals, Inc.		
	AG	EP 0570594 A	11/24/1993	SHIONOGI & CO., LTD.		
	AH	WO 97/29776 A1	8/21/1997	G.D. Searle & Co.		
	AI	EP 0 847 992 A1	6/17/1998	Mitsui Chemicals, Inc.		
	AJ	WO 01/70675	9/27/2001	METHYLGENE, INC.		
	AK	WO 02/26696	4/4/2002	PROLIFIX LIMITED		
	AL	WO 02/46129 A2	6/13/2002	Abbott Laboratories		
	AM	WO 03/024448 A2 & A3	3/27/2003	Methylgene, Inc.		
	AN	WO 03/039599 A1	5/15/2003	Novartis AG		
	AO	WO 03/066579 A2	8/14/2003	Arys Pharmaceuticals		
	AP	WO 2004/046094	6/3/2004	Queen Mary & Westfield College		
	AQ	WO 2005/019174	3/3/2005	Arys Pharmaceuticals, Inc.		
	AR	WO 2005/040161	5/6/2005	S*Bio PTE		
	AS	WO 2005/040101	5/6/2005	S*Bio PTE		
CC	AT	WO 2005/073180	8/11/2005	JKUREHA CHEMICAL INDUSTRY COMPANY, LIMITED		

Examiner Signature	/Celia Chang/	Date Considered	08/22/2006
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.